Meta-analysis reveals Ide-cel has lower overall response rate, while demonstrating increased risks of cytokine release syndrome compared to Cilta-cel in RRMM.
Key Points
Patients treated with Cilta-cel had over three times greater odds of achieving an overall response compared to Ide-cel.
The meta-analysis incorporates 20 studies with a total of 3,217 patients evaluating treatment responses and adverse events.
Assessment of the effectiveness and safety profiles of CAR T-cell therapies demonstrates significant differences in response rates and AEs.
Findings indicate that treatment selection for RRMM should consider both efficacy and associated toxicity profiles.